Varian gets FDA clearance for eye cancer proton

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Varian Medical Systems Inc. has received FDA 510(k) clearance for a new proton therapy eye dose calculation module that has been made part of the company's Eclipse treatment planning system for planning radiation therapies for the treatment of cancer.

The new proton eye dose calculation module enables doctors to create the highly complex treatment plans necessary for precisely delivering proton radiation beams for treatment of ocular cancers while offering protection for the many small, essential critical structures in and around the human eye. This is the first such product cleared by the FDA for use in the United States, according to Varian.